Manchester Child Lung Clinic

Call Me

0161 696 5294
0161 495 7000
0161 447 6600
0161 447 6700

Connect With Email

Clinic Timing

BMI Alexandra Hospital

Tuesday: 6.30pM - 8pm

Spire Manchester Hospital

Friday: 10.30am - 12.30pm

My Research

What is research and why is it important to me? Research is about finding out new knowledge that could lead to changes in treatments, policies or care. In other words, research is my way of understanding the needs and help speedy recovery of my little patients. My focus of research has been on Asthma, epidemiology of common respiratory illnesses, Cystic Fibrosis, Primary ciliary dyskinesia and Non cystic fibrosis bronchiectasis. Here is a sample of some of the research that I have undertaken as a Principal Investigator.

CF START: The cystic fibrosis (CF) anti-staphylococcal antibiotic prophylaxis trial (CF START); a randomised registry trial to assess the safety and efficacy of flucloxacillin as a longterm prophylaxis agent for infants with CF. Non-commercial. Ongoing. Non – commercial

ALPINE 2: AZLI for children with CF and PA lung infection – Randomized, Double-Blind, Phase 3B Trial to Evaluate the Safety and Efficacy of 2 Treatment Regimens of Aztreonam 75 mg Powder and Solvent for Nebulizer Solution / Aztreonam for Inhalation Solution (AZLI) in Pediatric Subjects with Cystic Fibrosis (CF) and New Onset Respiratory Tract Pseudomonas aeruginosa (PA) Infection/Colonization (Gilead Pharmaceuticals). Opening soon. Commercial

VX15-770-126 ARRIVAL Extension Study: A Phase 3, 2-Arm, Open-label Study to Evaluate the Safety and Pharmacodynamics of Long-term Ivacaftor Treatment in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age at Treatment (Vertex Pharmaceuticals). Ongoing. Commercial

VX15-770-124 ARRIVAL Study: A Phase 3, 2 Part, Open-Label Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Ivacaftor in Subjects With Cystic Fibrosis Who are Less than 24 Months of Age at Treatment Initiation and Have a CFTR Gating Mutation (Vertex Pharmaceuticals). Completed. Commercial

Cystic Fibrosis: The impact of Cystic Fibrosis on children, young people, adults and their families. Open. Non-commercial

VX15-371-101: A Phase 2a, Randomized, Double-blind, Placebo-controlled, Incomplete Block, Crossover Study to Evaluate the Safety and Efficacy of VX-371 in Subjects Aged 12 Years or Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation, and Being Treated With Orkambi (Vertex Pharmaceuticals). Completed. Commercial

LCI –SEARCH: Lung Clearance Index (LCI) as a Sensitive measure of Early Airway Change in Cystic Fibrosis (Use of lung clearance index to improve detection of changes in lung function in cystic fibrosis). Non-commercial. Completed

Caregiver Burden in Cystic Fibrosis: Exploring the caregiver burden of Cystic Fibrosis in the United States, Germany, United Kingdom, and Ireland (Vertex Pharmaceuticals). Completed. Commercial